Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neutrophil to lymphocyte ratio to define efficacy of the treatment with Ipilimumab or BRAF inhibitors (vemurafenib or dabrafenib) in patients with unresectable Stage III or IV melanoma

Next Previous
X
Search
Trial Profile

Neutrophil to lymphocyte ratio to define efficacy of the treatment with Ipilimumab or BRAF inhibitors (vemurafenib or dabrafenib) in patients with unresectable Stage III or IV melanoma

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabrafenib (Primary) ; Ipilimumab (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 26 Jul 2016 New trial record
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top